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ABSTRACT A positive correlation between virus evolutionary rate and disease pro-
gression has been shown for human immunodeﬁciency virus type 1 (HIV-1) infec-
tion. Much less is known about HIV-2, the second causative agent of AIDS. We
analyzed 528 HIV-2 env V1-C3 sequences generated from longitudinal plasma
samples that were collected from 16 study participants during a median observa-
tion time of 7.9 years (interquartile range [IQR], 5.2 to 14.0 years). Study partici-
pants were classiﬁed as faster or slower disease progressors based on longitudi-
nal CD4 T-cell data. The HIV-2 evolutionary rate was signiﬁcantly associated
with CD4 T-cell levels and was almost twice as high among the faster progres-
sors as among the slower progressors. Higher evolutionary rates were accounted
for by both synonymous and nonsynonymous nucleotide substitutions. More-
over, slow disease progression was associated with stronger positive selection on
HIV-2/SIVsm (simian immunodeﬁciency virus infecting sooty mangabey) surface-
exposed conserved residues. This study demonstrated a number of previously
unknown characteristics linking HIV-2 disease progression with virus evolution.
Some of these ﬁndings distinguish HIV-2 from HIV-1 and may contribute to the
understanding of differences in pathogenesis.
IMPORTANCE The relationship between HIV evolution and disease progression is
fundamental to our understanding of HIV immune control and vaccine design. There
are no clear deﬁnitions for faster and slower HIV-2 disease progression and for the
relationship of the rate of progression with HIV-2 evolution. To address the hypothe-
sis that viral evolution is correlated with disease progression in HIV-2 infection, we
determined faster and slower disease progression based on follow-up data from a
prospective cohort of police ofﬁcers in Guinea-Bissau. The analysis showed that al-
though the CD4 T-cell level and the decline in the level were independently asso-
ciated with progression to AIDS, only the CD4 T-cell level or a combined CD4
T-cell level/decline stratiﬁcation was associated with the rate of HIV-2 evolution. The
HIV-2 evolutionary rate was almost twice as high among the faster progressors as
among the slower progressors. Importantly, this report deﬁnes previously unknown
characteristics linking HIV-2 disease progression with virus evolution.
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It has been estimated that one million to two million people worldwide are infectedwith HIV-2 (1). Similarly to HIV-1, HIV-2 causes AIDS, but with lower rates of trans-
mission, CD4 T-cell decline, and disease progression (2). Despite similar levels of
integrated viral DNA (proviral DNA), the plasma viral RNA burden (viral load) at
comparable CD4 T-cell counts is signiﬁcantly lower in HIV-2 infections than in HIV-1
infections, suggesting either that HIV-2 is associated with a lower rate of replication or
that HIV-2 is more susceptible to immune control (2–8). However, despite the lower
level of chronic immune activation in HIV-2 infection, both viruses elicit several immune
responses that may modulate disease progression, e.g., neutralizing antibodies and
cytotoxic T lymphocytes (2).
The natural history of HIV-2 infection was not known in detail until recently, and
cohort data often lack information on the estimated time of HIV-2 infection, precluding
assessment of the true rates of HIV-2 disease progression and of the dynamics of CD4
T-cell change and plasma viral load during infection (9, 10). In a recent study, we
showed that most individuals infected by HIV-2 progress to disease but at a lower rate
than for HIV-1 (11). Moreover, the role of CD4 T-cell dynamics in HIV-2 infection was
shown to be a strong clinical predictor of disease progression. Thus, both HIV-1 disease
progression and HIV-2 disease progression are associated with CD4 T-cell decline and
early initial postseroconversion CD4 T-cell levels (11–15).
Both HIV-1 and HIV-2 evolve rapidly due to high mutation rates, high replication
rates, and fast generation times (16). This results in extensive genetic variability
both within and between infected individuals. The association between viral evo-
lutionary rate (5, 17) and disease progression has been studied extensively for
HIV-1, and most studies have suggested that these parameters are positively
correlated (18). Much less is known about HIV-2 intrapatient evolution; whereas
some researchers have reported that HIV-2 has a lower evolutionary rate than HIV-1,
others have reported the opposite (5, 17, 19–21). However, no correlation has been
found between the virus evolutionary rate and variations in levels of CD4 T-cells
over time in HIV-2 infection (5, 20). Importantly, those studies were performed on
proviral DNA or on RNA obtained from virus propagated in culture, which may not
reﬂect the circulating virus populations. To the best of our knowledge, differences
in HIV-2 evolutionary rates between groups with different rates of disease progres-
sion have not been investigated.
Here, we aimed to determine whether faster disease progression and slower disease
progression are differentiated by rates of decline of and levels of CD4 T cells in HIV-2
infection, similarly to what has been previously suggested to be the case in HIV-1
infection (12, 14), and investigated the association between the disease progression
rate and the evolutionary dynamics of HIV-2.
RESULTS
Study population. The HIV-2 env V1-C3 region was successfully reverse tran-
scribed and ampliﬁed from 53 plasma samples that had been collected longitudi-
nally from 16 study participants of a well-described cohort of police ofﬁcers in
Guinea-Bissau (22, 23). Inclusion criteria and clinical characteristics are presented in
Materials and Methods (see also Table S1 and S2 at https://dochub.com/patrik
-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD__
sa_SKWC-XzVE). The median observation time from inclusion until the last registered
visit for the 16 included individuals was 19.2 years (interquartile range [IQR], 15.0 to 20.8
years). A median of seven clones from each time point were sequenced, and the
median time between the collection dates of the ﬁrst and last ampliﬁed patient-speciﬁc
samples was 7.9 years (IQR, 5.2 to 14.0 years). Among the 528 sequences, 119 putative
recombinant sequences were removed, leaving 409 sequences for evolutionary analy-
ses. Phylogenetic subtype analysis showed that all sequences belonged to HIV-2 group
A. Moreover, all sequences from each individual formed distinctive monophyletic
clades in the phylogeny, indicating that sequences from the study participants were
not subjected to superinfection, coinfection, mix-up during sample handling, or con-
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tamination during the laboratory procedures (see Fig. S1 at https://dochub.com/patrik
-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD
__sa_SKWC-XzVE).
Classiﬁcation of individuals as faster and slower progressors based on longi-
tudinal CD4 T-cell dynamics. To assess the link between HIV-2 evolutionary esti-
mates and disease progression, we classiﬁed the study participants into groups of faster
disease progressors and slower disease progressors based on longitudinal CD4 T-cell
dynamics from the entire HIV-2-infected population of the Guinea-Bissau police cohort.
To determine if faster disease progression can be differentiated from slower disease
progression by CD4 T-cell decline and level in cases of HIV-2 infection also, as had
been previously suggested for HIV-1 infection (12, 14), we analyzed the time to the
appearance of AIDS from the ﬁrst recorded percentages of CD4 (CD4%) for all HIV-2-
infected individuals in the cohort with two or more CD4% measurements (n 192).
Three stratiﬁcations were used, and faster and slower progressors were deﬁned as those
patients whose CD4% values were above and below themean of the values determined for
all participants for each stratiﬁcation, respectively (Fig. 1). The ﬁrst stratiﬁcation, referred to
as the CD4% decline rate, was based on individual coefﬁcients of regression for CD4%.
Eighty-one participants were classiﬁed as faster progressors (mean CD4% decline, 2.7% per
year [standard deviation {SD}, 2.6]) and 111 as slower progressors (mean CD4% increase,
0.5% per year [SD, 1.6]). The median time to AIDS from the ﬁrst recorded CD4% value was
11.7 years (95% conﬁdence interval [CI], 7.3 to 16.1 years) for faster progressors with a faster
CD4% decline and 16.8 years (CI, 12.3 to 21.3 years) for slower progressors with a slower
CD4% decline (P 0.008 [log rank test]) (Fig. 1A). The second stratiﬁcation, referred to here
as the CD4% level, was determined as the CD4% level at the midpoint in time between the
ﬁrst and last recorded CD4% levels using the regression line generated in the ﬁrst stratiﬁ-
cation. Eighty-seven participants were classiﬁed as faster progressors (mean CD4% level,
21.0% [SD, 4.3%]) and 105 as slower progressors (mean CD4% level, 35.0% [SD, 5.7%]). The
median time to AIDS from the ﬁrst recorded CD4% value was 9.4 years (95% CI, 6.7 to
12.1 years) for faster progressors with a low CD4% level and 15.5 years (95% CI, 14.3 to
16.6 years) in slower progressors with a high CD4% level (P 0.001 [log rank test]) (Fig. 1B).
In the third stratiﬁcation, referred to as the combined coefﬁcient, the CD4% decline rate and
CD4% level were combined to have equal inﬂuences on the stratiﬁcation (see Materials and
Methods). Eighty-ﬁve participants were classiﬁed as faster progressors (combined coefﬁ-
111 78 41 21 1 0
81 39 22 8 2 0
2520151050
High combined coeﬃcient
Low combined coeﬃcient
2520151050
1.0
0.8
0.6
0.4
0.2
0.0
Slow CD4% decline
Fast CD4% decline
2520151050
High CD4% level
Low CD4% level
105 70 37 16 2 0
87 47 26 13 1 0
107 74 39 18 2 0
85 43 24 11 1 0
* *
*
* *
*
FIG 1 Kaplan-Meier curves of AIDS-free time. Three stratiﬁcations were explored (fast and slow progressors were deﬁned by having values above
or below the mean values from all participants for each stratiﬁcation). (A) CD4% decline rate. (B) CD4% level at the midpoint in time between
the ﬁrst and last recorded CD4% values. (C) Combined effect of CD4% decline rate and CD4% level. Tick marks indicate participants with censored
data. Asterisks indicate the time points in each group when ﬁve participants were still at mortality risk and at risk of developing AIDS. The numbers
of individuals at risk are given below the ﬁgure panels at 5-year intervals. Data from faster progressors are shown in vermillion, and data from
slower progressors are shown in blue.
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cient below the mean) and 107 as slower progressors (combined coefﬁcient above the
mean). The median time to AIDS from the ﬁrst recorded CD4% value was 8.6 years (95% CI,
6.5 to 10.8 years) for faster progressors with a low combined coefﬁcient and 18.7 years (95%
CI, 13.6 to 23.8 years) for slower progressors with a high combined coefﬁcient (P 0.001
[log rank test]) (Fig. 1C). Interestingly, only 50% of the participants were consistently
classiﬁed as faster or slower progressors in the stratiﬁcations (see Table S3 at https://dochub
.com/patrik-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822?dt
Nx2HKD__sa_SKWC-XzVE). A Cox proportional-hazards model with CD4% decline and
level as discrete covariates (according to the stratiﬁcations described above) showed that
CD4% decline and level were independently associated with disease progression rate
(P 0.007 for CD4% decline and P 0.001 for CD4% level [Wald test]; the independence of
these covariates was determined by a nonsigniﬁcant interaction term between the cova-
riates corresponding to P 0.85 [Wald test]).
The HIV-2 evolutionary rate is associated with CD4% level and combined
coefﬁcient but not with CD4% decline alone. Since all three stratiﬁcations described
above were signiﬁcantly linked to the rate of disease progression, we decided to assess
differences in virus evolutionary parameters for all three stratiﬁcations (Table 1). Model
evaluation within the hierarchical phylogenetic modeling (HPM) framework indicated
that a strict clock with a constant size demographic model generally ﬁtted our data best
for both the nucleotide and codon models (see Materials and Methods and Text S1 at
https://dochub.com/patrik-medstrand/zqp8z8/supplemntaryinformation_palm_mbio
_ver2_180822?dtNx2HKD__sa_SKWC-XzVE for details). The overall mean evolutionary
rate of the V1-C3 region was 23.5 103 codon substitutions/site/year (95% highest
posterior density [HPD] interval, 20.3 103 to 26.6 103) (Table 2). No association
was found between evolutionary rate and disease progression when individuals were
classiﬁed as faster or slower progressors based on CD4% decline rate (Bayes factor
[BF] 0.3) (Table 2). In contrast, when individuals were classiﬁed based on either CD4%
level or the combined coefﬁcient, the mean evolutionary rate was signiﬁcantly higher
in faster progressors (28.6 103 codon substitutions/site/year; 95% HPD, 24.2 103
to 33.5 103) than in slower progressors (14.9 103 codon substitutions/site/year;
95% HPD, 12.2 103 to 17.6 103) (BF 20.3) (Table 2). Similar differences were
TABLE 1 Disease progression classiﬁcations of all individuals, based on three different
stratiﬁcations for CD4% (n  16)
Individual
CD4% decline
rate/year CD4% level Combined coefﬁcient
Valuea Progressorb Valuea Progressorb Valuea,c Progressorb
DL3405 1.46 Slow 33.95 Slow 1.00 Slow
DL3542 0.69 Fast 32.73 Slow 0.74 Slow
DL2051 1.61 Fast 31.11 Slow 0.62 Slow
DL2876 0.55 Fast 28.91 Slow 0.67 Slow
DL3654 0.15 Slow 27.74 Slow 0.70 Slow
DL2533 1.10 Slow 23.96 Slow 0.68 Slow
DL2316 1.10 Fast 23.45 Fast 0.50 Fast
DL2794 0.11 Slow 20.99 Fast 0.53 Fast
DL3941 3.40 Fast 20.65 Fast 0.29 Fast
DL2381 1.17 Fast 20.62 Fast 0.44 Fast
DL2335 0.58 Fast 20.41 Fast 0.47 Fast
DL3647 0.73 Fast 19.63 Fast 0.44 Fast
DL3646 0.33 Slow 19.32 Fast 0.46 Fast
DL3222 0.88 Slow 19.25 Fast 0.53 Fast
DL3740 0.69 Slow 17.57 Fast 0.48 Fast
DL2386 1.61 Fast 16.29 Fast 0.32 Fast
aData represent individual values for the three different stratiﬁcations.
bIndividuals with values above or below the mean values determined for all individuals were grouped as
faster or slower progressors, respectively.
cThe combined coefﬁcient values represent a combination of CD4% decline rate and CD4% level. The
combined coefﬁcient values were obtained by transforming the CD4% decline rate values and CD4% level
values, setting them to comparable scales, and subsequently multiplying them.
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found for the nucleotide substitution rate (BF 0.3 for association with CD4% decline
rate and BF 17.5 for association with CD4% level or the combined coefﬁcient) (see
Table S4 at https://dochub.com/patrik-medstrand/zqp8z8/supplemntaryinformation
_palm_mbio_ver2_180822?dtNx2HKD__sa_SKWC-XzVE).
Higher evolutionary rate in the HIV-2 V1V2 and C3 region than in the C2 and
V3 region. To determine if the evolutionary rates were similar in different regions of
env, we partitioned the data set into four well-deﬁned regions: V1V2, C2, V3, and C3.
The evolutionary rate was higher in both the V1V2 and C3 regions than in the C2 and
V3 regions, respectively (Table 2) (P 0.05 [Wilcoxon signed rank test with Bonferroni
correction for all pairwise comparisons]). No signiﬁcant difference was found between
faster and slower progressors in any of the four V1-C3 regions when individuals were
stratiﬁed by CD4% decline rate (BF values ranged from 0.2 to 0.3). In contrast, moderate
to strong associations between evolutionary rate and disease progression were found
in the V1V2 (BF 11.8), C2 (BF 28.4), and C3 (BF 6.1) regions for individuals
grouped according to CD4% level or the combined coefﬁcient. A weak association was
also noted in the V3 region (BF 2.4).
Since the CD4% level and the combined coefﬁcient stratiﬁcations resulted in iden-
tical groupings (Table 1) and all analyses indicated a strong association between
evolutionary rate and CD4% level—in contrast to the absence of associations between
evolutionary rate and CD4% decline rate—only results based on the CD4% level
stratiﬁcation are presented for the subsequent analyses.
V1-C3 of HIV-2 env evolves under conditions of negative selection. Next, we
hypothesized that the differences in evolutionary rate between the progressor groups
could have originated in parameters inﬂuencing selection pressure or viral replication.
We therefore estimated the ratio of nonsynonymous substitution rates to synonymous
substitution rates (the dN/dS rate ratio), which indicates whether a gene or site had
been subjected to positive selection (dN/dS 1) or to negative selection (dN/dS 1) or
had evolved neutrally (dN/dS 1). We found global negative selection over the entire
V1-C3 region (dN/dS rate ratio 0.56; 95% HPD interval, 0.49 to 0.63), with no statistical
differences apparent between faster and slower progressors (BF 1.3) (see Table S5 at
https://dochub.com/patrik-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_
ver2_180822?dtNx2HKD__sa_SKWC-XzVE). The region-speciﬁc analyses showed that
the V1V2 and C3 regions evolved neutrally (dN/dS rate ratios, 1.27 [95% HPD interval,
0.84 to 1.80] and 0.94 [95% HPD interval, 0.70 to 1.22], respectively) whereas the C2 and
V3 regions had been subjected to strong negative selection (dN/dS rate ratios, 0.22
[95% HPD interval, 0.18 to 0.27] and 0.41 [95% HPD interval, 0.27 to 0.57], respectively).
No signiﬁcant differences were found in dN/dS rate ratios between the progressor
groups in the V1V2, V3, or C3 regions (BF values of 3 for all regions), whereas a
moderately higher level of negative selection was found in the C2 region among faster
TABLE 2 Evolutionary rates (103 codon substitutions/site/year) in the V1-C3 env regions determined using a strict clock hierarchical
phylogenetic modela
Genetic
region
All
individualsc
CD4% stratiﬁcation
CD4% decline rate CD4% level and the combined coefﬁcientb
Fast
progressorsc
Slow
progressorsc Bayes factord
Fast
progressorsc
Slow
progressorsc Bayes factord
V1-C3 23.5 (20.3-26.6) 24.7 (20.1-29.6) 21.9 (19.1-24.9) 0.3 28.6 (24.2-33.5) 14.9 (12.2-17.6) 20.3
V1V2 29.5 (25.1-34.2)a 30.1 (24.6-36.0) 28.8 (23.7-34.0) 0.3 35.4 (28.9-42.2) 19.6 (14.8-24.7) 11.8
C2 18.0 (15.2-20.7)a 18.6 (15.3-21.9) 16.7 (13.9-19.5) 0.3 21.5 (17.6-25.7) 12.0 (9.2-15.2) 28.4
V3 21.2 (17.0-25.7)a 21.6 (16.5-26.8) 20.8 (15.7-25.9) 0.3 24.1 (18.0-30.6) 16.5 (11.0-22.2) 2.4
C3 26.6 (22.6-31.1)a 27.0 (22.0-32.4) 26.0 (21.6-30.6) 0.2 30.4 (24.3-27.0) 20.2 (15.2-25.8) 6.1
aP values for Wilcoxon signed rank tests for comparisons of rates between regions were as follows: for V1V2 versus C2, 0.001; for V1V2 versus V3, 0.002; for V1V2
versus C3, 1; for C2 versus V3, 0.005; for C2 versus C3, 0.001; for V3 versus C3, 0.001.
bThe combined coefﬁcient values represent a combination of CD4% decline rate and CD4% level.
cData correspond to 103 codon substitutions per site per year (95% highest posterior density interval).
dBayes factor (BF) support for association between codon substitution rate and disease progression (faster versus slower progressors). BF 3 was considered evidence
of a signiﬁcant association.
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progressors than among the slower progressors (BF 3.7) (see Table S5 at https://
dochub.com/patrik-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2_
180822?dtNx2HKD__sa_SKWC-XzVE).
Higher nonsynonymous and synonymous substitution rates in faster progres-
sors than in slower progressors. Whereas the dN/dS rate ratio provides an estimate
of the overall selective pressure, analyses of expected nonsynonymous (E[N]) and
expected synonymous (E[S]) substitution rates can add detailed information con-
cerning replication and selection pressure (17). The E[N] and E[S] divergences were
estimated and plotted as accumulated divergence rates over time from the ﬁrst
analyzed sample (Fig. 2; see also Table S6 at https://dochub.com/patrik-medstrand/
zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD__sa_SKWC-XzVE).
The HIV-2 divergence rates increased in a relatively linear manner during the asymp-
tomatic phase of infection, and viral populations in faster progressors accumulated
both nonsynonymous and synonymous substitutions faster than those in slower pro-
gressors. The median E[N] rate ranged from 3.0 103 to 6.6 103 nucleotide [nt]
substitutions/site/year for faster progressors and from 1.4 103 to 4.6 103 nt
substitutions/site/year for slower progressors (P 0.005 [two-tailed Mann-Whitney U
test {M-W}]). The median E[S] rate ranged from 4.5 103 to 11.2 103 nt substitu-
tions/site/year for faster progressors and from 1.1 103 to 4.0 103 nt substitu-
tions/site/year for slower progressors (P 0.001 [M-W]). These results are in line with
the higher overall viral evolutionary rates for faster progressors than for slower pro-
gressors seen in the HPM analyses and clarify why no statistically signiﬁcant differences
were found in dN/dS rate ratios.
Higher number of conserved sites under conditions of positive selection in
slower HIV-2 disease progression. Although the analysis described above indicated
the presence of general negative selection across the entire V1-C3 region, we hypoth-
esized that a number of speciﬁc residues could have been subject to positive selection.
To assess this hypothesis, we used a Renaissance counting procedure to estimate the
dN/dS rate ratio at each codon site (Fig. 3). Only a low proportion of sites showed
signatures of positive selection, and the proportions of positively selected sites were
not signiﬁcantly different between the viral populations of faster and slower progres-
sors across the V1-C3 region (7% and 11%, respectively; P 0.503 [M-W]) or in the
V1-C3 regions in separate analyses (see Table S7 at https://dochub.com/patrik-
medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD
__sa_SKWC-XzVE). While the numbers of sites under positive selection were similar in
the faster and slower progressors in the V1V2, V3, and C3 regions, slower progressors
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FIG 2 Synonymous and nonsynonymous divergence over time. Data represent accumulated synonymous and nonsynonymous divergences over time in the
V1-C3 env region of HIV-2 for each study participant. The divergence from the level seen with the ﬁrst analyzed sample from each study participant is shown.
Data from faster progressors are shown in vermillion, and data from slower progressors are shown in blue.
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had more sites under positive selection in the C2 region than faster progressors (35
versus 20 sites) (P 0.026 [two-tailed Fisher’s exact test {FET}]) (Fig. 3). Since it has been
shown that the HIV-2 C2 and C3 regions are exposed similarly to the corresponding
HIV-1 regions and are under negative selection, we hypothesized that the effects of
positive selection on amino acids subjected to structural and functional constraints
would negatively impact viral ﬁtness (24). We therefore deﬁned the amino acids critical
to viral ﬁtness as those amino acids that were conserved between HIV-2 and the simian
immunodeﬁciency virus (SIV) from which HIV-2 originated through cross-species trans-
mission (i.e., SIVsm, the SIV infecting sooty mangabeys [Cercocebus atys]) and compared
the ratios of positive selection of viral lineages between slower and faster progressors
(25). Among the 246 amino acids in the V1-C3 regions, 84 were conserved between
SIVsm and HIV-2 (see Table S8 at https://dochub.com/patrik-medstrand/zqp8z8/
supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD__sa_SKWC-XzVE).
Comparisons of the numbers of conserved HIV-2/SIVsm sites under positive selection
showed that slower progressors had more conserved sites under positive selection than
faster progressors (20 versus 5 sites (P 0.002 [FET]) in the V1-C3 region. The differ-
ences between the slower and faster progressors with respect to positive selection at
conserved sites were most highly pronounced in the C2 region (12 versus 3 sites,
respectively) (P  0.021 [FET]), while such differences were not observed in the
V1V2, V3, and C3 regions. To conﬁrm previous observations that C2 is well exposed
on the HIV-2 env gene, we used the published structural data of HIV-2 gp125 to
visualize the amino acids in the V1-C3 region (24, 26). This analysis indicated that the
majority (15 of 22) amino acids associated with positive selection mapped to exposed
surfaces on HIV-2 gp125 (see Fig. S2 at https://dochub.com/patrik-medstrand/zqp8z8/
supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD__sa_SKWC-XzVE). More-
over, the surface accessibility of amino acids within the V1-C3 regions showed that the
FIG 3 Codon-speciﬁc selective pressure. The selective pressures at each codon site of the sequence alignment of the env V1-C3 region
of HIV-2 for faster and slower disease progressors are indicated. The proportions (y axis) with positive selection (vermillion or blue) or
negative selection (gray) at codon sites of the sequence alignment (x axis) are shown for faster progressors (upper graph) and slower
progressors (lower graph). Filled black circles indicate codons conserved between HIV-2/SIVsm strains associated with positive selection.
Vertical lines divide the fragment into env regions V1V2, C2, V3, and C3.
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positively selected sites were associated with residues with solvent-exposed surfaces in
the C2 region (29 of 68 amino acids) (P 0.040 [FET]).
DISCUSSION
The relationship between HIV evolution and disease progression is fundamental to
our understanding of HIV immune control and vaccine design. We recently showed an
association between CD4 T-cell decline/CD4 T-cell level and HIV-2 disease progres-
sion rate (11). Here we deﬁned relatively faster and slower HIV-2 disease progression
using these associations and dissected the associations between HIV-2 evolutionary
dynamics and disease progression. Studies addressing these associations for HIV-2
infection have been limited (5, 17, 20, 27). In HIV-2 infection, disease in many patients
progresses slowly, but in some the advance is as fast as that in HIV-1 infection (28–30).
The reasons for this marked heterogeneity are currently not known, but mechanisms
similar to those of HIV-1 infection may be involved (11, 31). To address the hypothesis
that viral evolution is associated with disease progression in HIV-2 infection also, we
ﬁrst determined stratiﬁcations for relatively faster and slower disease progression based
on follow-up data from the entire prospective cohort of police ofﬁcers in Guinea-Bissau.
The analysis showed that although CD4 T-cell level and decline were independently
associated with progression to AIDS, the effect size was largest for the CD4% level or
the combined CD4% level/decline stratiﬁcations. This observation is in line with previ-
ous reports showing that the CD4 T-cell level at corresponding time points after
infection may be a better marker for both HIV-1 and HIV-2 disease progression rates
than CD4 T-cell decline (11, 12, 14). Moreover, only the CD4 T-cell level or the
combined CD4 T-cell level/decline stratiﬁcations were associated with the evolution-
ary rate of HIV-2. This observation suggests that the postseroconversion CD4 T-cell
level is associated with the rate of disease progression (32), whereas the rate of CD4
T-cell decline during chronic infection can be viewed as an additive component
inﬂuencing progression in combination with the initial CD4 T-cell levels. The reasons
for and mechanisms that determine the variability of CD4 T-cell decline range from
genetic and biological factors to physiological factors (33, 34). In those with a low
postseroconversion level of CD4 cells, progression to AIDS is faster (and the time to
AIDS shorter) than among those with a higher postseroconversion level of CD4 cells
(11). It is possible that events that occur during acute infection dictate the initial
postseroconversion levels of CD4 T-positive (T) cells in HIV-2 infection also (11, 32).
Thus, a broader assessment of disease progression may provide additional understand-
ing of the mechanisms that drive the disease pathogenesis.
Many HIV-2-infected individuals remain nonprogressors with low viral loads during
the course of infection, and HIV-2 sequences can be obtained only from individuals
with detectable plasma viral loads (35). Hence, HIV-2-infected individuals without
detectable viremia cannot be assessed in studies of HIV-2 evolution in plasma. How-
ever, our assay had a detection limit of 12 RNA copies/ml plasma, indicating that even
slow progressors with low viral loads (50 copies/ml plasma) could be detected.
A strong association between HIV-2 evolutionary rate and disease progression was
found in all the studied genetic subregions, except for V3. For HIV-1, the ﬂanking V3
region is known to be highly exposed and immunodominant (36). By contrast, the V3
region of HIV-2 has been suggested to be more highly concealed from the immune
system and to be the least entropic and positively selected part of the C2-C3 region
(24). Our ﬁndings of lower evolutionary rates and stronger purifying selection in the C2
and V3 regions support previous suggestions that the immune response of HIV-2-
infected individuals may be more highly directed to other regions of the HIV-2
envelope (27, 37, 38).
Our HIV-2 evolutionary rate estimates are in the range of what has been reported by
others, although direct comparisons are difﬁcult due to differences in the env regions
analyzed and to the use of different phylogenetic models (17, 20, 21). In a previous
study of HIV-1 subtype B based on a similar methodological approach, the evolutionary
rate of the HIV-1 V1-V3 region was estimated to be approximately twice as high as our
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estimates for HIV-2 (39). The uncertainty of how the HIV-2 evolutionary rate compares
with the rate of HIV-1 highlights the need for a direct comparison of HIV-1 evolution to
HIV-2 evolution in the same population using the same approaches. Previous studies of
HIV-2 intrahost evolution have been based on limited numbers of individuals and time
points. The generally low viral loads among HIV-2-infected individuals continue to
present a large technical challenge and are likely to have contributed to the paucity of
intrahost HIV-2 evolutionary studies (6–8).
In a stratiﬁed analysis, we found that both nonsynonymous and synonymous
substitutions accumulated at a higher rate in faster progressors than in slower pro-
gressors. This result suggests generally faster replication rates and shorter generation
times for virus populations in faster progressors and is in line with previous reports of
increased virus replication rates among immunosuppressed individuals infected with
HIV-2 (40). It is possible that increased replication rates can reduce the generation time
in intrahost virus populations and can lead to higher rates of neutral evolution. This has
also been suggested to explain the association between disease progression and
synonymous substitution rates in HIV-1 infection (17, 41).
Previous studies have demonstrated that the env gene is under purifying selective
pressure overall in both HIV-1 and HIV-2 infection, with a few irregularly distributed
positively selected sites (42, 43). Comparisons between HIV-1 disease progressor groups
have suggested that slow-disease progressors are associated with a higher number of
positively selected sites (44). Similarly to HIV-1 data, we identiﬁed a few positively
selected sites in the majority of HIV-2 slow progressors. However, the mean dN/dS rate
ratios and the proportions of positively selected sites did not differ between slower and
faster progressors. Instead, we found that slow HIV-2 disease progression was associ-
ated with a higher level of positive selection on a selected number of surface-exposed
residues conserved between HIV-2/SIVsm. It is tempting to speculate that slow pro-
gressors may elicit a stronger immune response to highly surface-exposed conserved
residues, which may in turn impact viral ﬁtness, since such conserved amino acids are
likely to have a functional and structural impact on envelope functions (24, 27, 45). If
true, our ﬁndings would be consistent with the concept that hosts who mount a
stronger immune response against the infecting virus have greater numbers of posi-
tively selected sites and progress to AIDS at a lower rate, which is reﬂected by higher
postseroconversion CD4 T-cell levels (44). In line with this, Bohl et al. showed that
mutations of conserved residues of HIV-2 envelope resulted in poor envelope function
(46).
In conclusion, our analyses show a strong association between HIV-2 evolutionary
rate and disease progression as determined by CD4% levels. Overall negative selection
was demonstrated in the analyzed HIV-2 env fragment, with the proportion of positively
selected sites in the range of what has been shown for HIV-1. Interestingly, slow disease
progression among HIV-2-infected individuals was associated with higher levels of
positive selection on residues conserved between HIV-2 and SIVsm, which may indicate
generally reduced viral ﬁtness among these viral variants. Our ﬁndings provide new
insights into the associations between pathogenesis and intrahost evolution of HIV-2.
Still, more studies on how the dynamics of disease progression rate is shaped by the
molecular evolution of HIV-2 are warranted. Further knowledge of HIV-2 pathogenesis
and comparisons between HIV-1 and HIV-2 will be important to reveal fundamental
differences in how these two viruses cause immunodeﬁciency.
MATERIALS AND METHODS
Study population. This study included individuals from a large cohort of police ofﬁcers in Guinea-
Bissau, West Africa, which was formed in 1990 (22, 23). At inclusion, and at follow-up visits scheduled
with an interval of 12 to 18 months, individuals were examined and a plasma sample was collected. The
civil war in 1998 to 1999 temporarily (from June 1998 until the end of 2002) ended inclusion, but annual
visits of previously included individuals were resumed in July 2000. The cohort was followed routinely
until February 2011, when the cohort was closed. In September 2013, however, selected individuals from
the cohort were asked to participate in a special sampling round, including a clinical examination and
collection of a plasma sample. In early 2006, the police cohort was included in the national antiretroviral
therapy (ART) program which was introduced into Guinea-Bissau in 2005. HIV testing was performed at
HIV-2 Disease Progression and Viral Evolutionary Rate ®
January/February 2019 Volume 10 Issue 1 e01245-18 mbio.asm.org 9
 o
n
 M
ay 19, 2019 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
the National Public Health Laboratory (LNSP), Bissau, as previously described (22). The CD4 T-cell count
and CD4% were determined at each follow-up visit after infection (14, 22, 23). In the absence of
commercial HIV-2 RNA assays, HIV-2-infected patients are generally monitored by CD4 T-cell levels,
particularly in areas of endemicity. Consequently, viral load measurements have not been included as a
standard procedure in Guinea-Bissau, preventing us from a comprehensive analysis of viral load data in
this study.
The cohort includes 438 seroincident and seroprevalent HIV-2-infected individuals, 83 of whom had
an estimated date of seroconversion, deﬁned as the midpoint between the last HIV-2 seronegative
sample collection date and the ﬁrst seropositive sample collection date. Individuals with long follow-up
series, including both CD4% measurements and available plasma samples, were considered for inclusion
in the study. Our initial goal was to conduct this study by including only individuals with estimated dates
of infection. Thus, ampliﬁcation of viral RNA was attempted on plasma samples from seroincident
individuals from whom three or more longitudinal plasma samples were available (n  19). As expected,
due to the generally low viral loads in HIV-2 infections, ampliﬁcation was successful for only a minority
of samples and seven individuals with two or more successfully ampliﬁed longitudinal samples could be
included in the study. We therefore decided to also include seroprevalent individuals (i.e., individuals
who were HIV-2 infected already at enrollment) in the study. Due to the anticipated difﬁculties in
amplifying HIV-2 RNA, only individuals with more than six available plasma samples were considered for
inclusion. Ampliﬁcation was attempted on samples from 19 individuals, and successful ampliﬁcation of
two or more longitudinal samples was achieved for 9 individuals. Taking the data together, ampliﬁcation
was attempted on samples from 38 individuals, where 16 individuals fulﬁlled the inclusion criterion of the
availability of two or more ampliﬁed longitudinal samples (total, 53 samples). The majority of the plasma
samples were collected from the 16 participants included in this study during the asymptomatic phase
of infection, deﬁned by a CD4 T-cell count of 200 cells/l, CD4% of 14, and a lack of clinical AIDS
symptoms (WHO stage 4 and CDC stage C [47, 48]). However, seven samples from six individuals were
collected after the individuals had developed AIDS, and two samples from two individuals were collected
after the individuals had initiated antiretroviral therapy (see Table S2 at https://dochub.com/patrik
-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD__sa_SKWC-XzVE).
Baseline characteristics of the 16 individuals are presented in Table S1 at https://dochub.com/patrik
-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD__sa_SKWC-XzVE,
and successfully ampliﬁed samples are listed in Table S2 at https://dochub.com/patrik-medstrand/
zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD__sa_SKWC-XzVE.
The 16 included individuals were subsequently stratiﬁed as faster or slower progressors using three
different parameters: CD4% decline rate, CD4% level, and a combined coefﬁcient. The combined
coefﬁcient was achieved by combining the CD4% decline rate and the CD4% level. Since these values
were quantiﬁed on different scales and since the CD4% decline rate could be either positive or negative,
we transformed the values before combining them. The two variables were transformed and rescaled to
have equal levels of inﬂuence on the combined coefﬁcient. More speciﬁcally, to account for negative
CD4% decline rates, all rates were transformed to positive rates with the corresponding relative
difference. Next, CD4% decline rates and CD4% levels were rescaled to include the same extrema.
Individual combined coefﬁcients were then determined for each study participants by multiplying the
rescaled CD4% decline rates and CD4% levels. There were no differences in age between the groups at
the time of the ﬁrst HIV-2-positive sample (data not shown).
Ampliﬁcation and sequencing. Viral RNA was extracted from patient plasma samples using an
miRNeasy microkit (Qiagen, Stockholm, Sweden) with minor modiﬁcations to the manufacturer’s instruc-
tions. Brieﬂy, 200 l of plasma was disrupted in 2,000 l QIAzol and loaded onto an RNeasy MinElute Spin
column in the presence of 15 g carrier RNA (Qiagen, Stockholm, Sweden). DNA was removed using an
on-column DNase treatment (Qiagen, Stockholm, Sweden), and puriﬁed RNA was eluted in 22 l
RNase-free H2O. An approximately 935-bp fragment that included the complete V1-C3 region of env (nt
6986 to 7920 in the BEN reference sequence]; GenBank accession number M30502) was ampliﬁed using
9.5 l eluted RNA in a SuperScript III One-Step reverse transcription-PCR (RT-PCR) system with Platinum
Taq DNA polymerase followed by a seminested PCR approach using Platinum Taq High Fidelity
(Invitrogen, Copenhagen, Denmark). Primers KH2_OF (5=-GAGACATCAATAAAACCATGTGTC-3=) and
TH2_OR (5=-TTCTGCCACCTCTGCACTAAAGG-3=) were used for One-Step PCR, and primers KH2_OF and
KH2_OR (5=-ACCCAATTGAGGAACCAAGTCA-3=) were used for nested PCR (5, 42). Following the initial
cDNA synthesis performed for 30 min at 50°C, the PCR conditions were identical for One-Step PCR and
the nested PCR: initial denaturation for 2 min at 94°C; 40 cycles of 15 s at 94°C, 30 s at 50°C, and 1 min
at 68°C; and a ﬁnal elongation step for 5 min at 68°C. The sensitivity of the PCR was found to be 12 RNA
copies/ml plasma as determined by a dilution series performed with an electron microscopy-counted
HIV-2 particle (Advanced Biotechnologies, Eldersburg, MD, USA). Molecular cloning of the ampliﬁed
fragments using a pCR2.1 TOPO cloning system (Invitrogen) was performed by BaseClear BV (Leiden, The
Netherlands), and 12 individual clones were routinely picked for subsequent sequencing on both strands
using conventional M13 primers.
Sequences were manually edited using CodonCode Aligner v1.5.2 (CodonCode Corporation, Ded-
ham, MA, USA) and aligned in MEGA5 using the Clustal algorithm (49). Sequences of poor quality and
sequences containing stop codons were removed from the analysis. Parts of the sequence that were
difﬁcult to align were removed in full codons to preserve an open reading frame, resulting in a ﬁnal
alignment length of 774 bp. The alignment spanned the last 30 bp in the 3= end of the C1 region, the
entire V1-C3 region, and the ﬁrst 6 bp in the 5= end of the V4 region. To analyze different subregions,
the fragment was partitioned as follows: V1V2, bp positions 31 to 201 (positions 7040 to 7318 in the BEN
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reference sequence); C2, positions 202 to 498 (7319 to 7615); V3, positions 499 to 600 (7616 to 7717); C3,
positions 601 to 768 (7718 to 7891).
Survival analysis. Kaplan-Meier analyses were performed for progression time to AIDS. Cases that
did not reach AIDS during follow-up were right censored at their last clinical examination date. Statistical
comparisons were performed by the log rank test. A Cox proportional-hazards model was applied to
determine independency of covariates (as deﬁned by nonsigniﬁcant interaction terms between covari-
ates).
Phylogenetic analysis. Putative intrapatient recombinant sequences were identiﬁed by the pairwise
homoplasy index (PHI) test using an exhaustive and iterative search algorithm and were then removed
from the data set (50) (the Perl script for the iterative search is available from the authors upon request).
Maximum likelihood (ML) phylogenetic trees were reconstructed using the inferred model, GTR I G,
with Garli v2.0 (51). Statistical support for internal branches was determined by ML-based approximate
likelihood ratio test (aLRT) Shimodaira-Hasegawa (SH)-like branch support, as implemented in PhyML 3.0
(52). SH values of0.9 were considered statistically signiﬁcant (53). For subtype analysis, our data set was
aligned with reference sequences of the major HIV-2 subtypes (downloaded from the Los Alamos
Sequence Database [54]) in MEGA5 using the Clustal algorithm (49), followed by phylogenetic analysis.
Evolutionary rate analysis. Analyses of HIV-2 evolutionary rates were performed in BEAST v1.7.5 (55)
by reconstructing Bayesian rooted and time-measured phylogenetic trees. Unless otherwise stated, all
analyses were performed by running a Markov chain Monte Carlo (MCMC) analysis for 50 106
generations, with sampling performed every 2,500 to 5,000 generations. Convergence was determined
by calculation of effective sample sizes (ESS) of 100 and inspection of traces, as assessed in Tracer v1.6
(available from http://beast.bio.ed.ac.uk/software/tracer/), following removal of 10% after burn-in. In
explorative analyses, we evaluated different models to ﬁnd the one that best ﬁt our data (see Table S9 at
https://dochub.com/patrik-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2
_180822?dtNx2HKD__sa_SKWC-XzVE). For each individual, the nucleotide substitution rates were
estimated using two different clock models (strict and uncorrelated lognormal relaxed clocks), two
different demographic models (Bayesian skyline plot and constant size), and either partitioned (1st plus
2nd and 3rd) or nonpartitioned codon positions. Nucleotide substitution rates were estimated using the
Hasegawa, Kishino, and Yano (HKY) substitution model (56) with gamma-distributed rates. Exploratory
analyses were performed by running a single analysis of 50 106 MCMC generations as described above.
All subsequent analysis were performed in duplicate, and the results were combined in LogCombiner
v1.7.5 after the removal of 10% after burn-in (55). Phylogenetic trees were visualized in Figtree v1.40
(available from http://tree.bio.ed.ac.uk/software/ﬁgtree/).
Hierarchical phylogenetic modeling (HPM) with ﬁxed effects, as implemented in BEAST v1.7.5, was
used to compare differences in evolutionary rate between progressor groups (55, 57). HPM allows
simultaneous analysis of sequence data from multiple individuals. Information of evolutionary parame-
ters is pooled across populations or individuals through hierarchical prior speciﬁcation, resulting in a
shrinkage effect of the variation when data are sparse for study participants. In addition, ﬁxed effects
across a group of individuals (in this case, the faster and slower progressor groups) can be included to
test and quantify differences between them. Analyses were performed using a strict or uncorrelated
lognormal relaxed clock model with a constant population size model as the tree prior. Both nucleotide
substitution rates (HKY) and codon substitution rates (determined using the GY94 codon model) were
estimated (56, 58). In a region-speciﬁc analysis, the data set was partitioned into the env V1V2, C2, V3 and
C3 regions and the evolutionary rate was estimated for all regions simultaneously by HPM (strict clock,
constant size, and GY94 codon model). Evolutionary rates were compared between groups as assessed
by Bayes factors (BFs). A BF value of 3 was considered to represent a signiﬁcant association (59).
Absolute rates and divergence plots. The ratio of nonsynonymous and synonymous substitution
rates (dN/dS rate ratio) has been widely used as an indicator of selection and molecular adaptation.
However, the dN/dS rate ratio cannot be used to detect simultaneous increases or simultaneous
decreases in nonsynonymous and synonymous rates (60). To address this issue and to further dissect and
explore the molecular adaptation process, the rate of substitution in every branch in a tree can be
divided into expected nonsynonymous (E[N]) and expected synonymous (E[S]) substitution rates. These
absolute rate estimates reﬂect the respective contributions of E[N] and E[S] substitution rates to the
overall substitution rate for a particular branch (17). These rates are uncorrected for the number of
possible nonsynonymous and synonymous alterations (i.e., the number of possible nonsynonymous
alterations is higher than the number of possible synonymous alterations). Consequently, direct com-
parisons between E[N] and E[S] estimates may be difﬁcult to interpret. However, relative differences
between, e.g., patient groups in E[N] or E[S] estimates can still be explored. Analyses of E[N] and E[S] and
divergence plots were performed as described by Lemey et al. (17). Brieﬂy, 200 random trees from the
HPM analysis (the model settings included HPM performed with a relaxed clock, constant population and
constant size, and the GY94 codon model [58]) were selected for each individual to determine E[N] and
E[S] rates in HyPhy 2.2.0 (61). The accumulated divergence was estimated and plotted over time using
the weighted average rate. The analysis was performed using a relaxed clock model because a strict clock
model, by deﬁnition, would assume a linear relationship.
Analysis of selected sites. A Renaissance counting approach, as implemented in BEAST v1.8.1(55),
was employed to estimate the ratio of nonsynonymous and synonymous substitutions at each codon
site, allowing identiﬁcation of sites that were under positive or negative selection (62). A dN/dS value of
1 suggests neutral selection, a dN/dS value of 1 suggests positive selection, and a dN/dS value of 1
suggests negative selection. The analysis was performed using a strict clock model with a constant
population size model as the tree prior and a triply partitioned (ﬁrst, second, and third) HKY nucleotide
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substitution model (56). Signiﬁcant positive or negative selection was considered to have occurred when
the HPD interval did not include a value of 1.
HIV-2/SIVsm conservation analysis. The env reference sequences of HIV-2 and SIVsm (n 61 and
n 54, respectively) were downloaded from the Los Alamos Database and aligned using the Clustal
algorithm. A strict consensus sequence was obtained using Consensus Maker (available at https://www
.hiv.lanl.gov/). Amino acid positions with 100% amino acid conservation were considered to represent
HIV-2/SIVsm conserved positions (see Table S8 at https://dochub.com/patrik-medstrand/zqp8z8/
supplemntaryinformation_palm_mbio_ver2_180822?dtNx2HKD__sa_SKWC-XzVE).
Surface accessibility. The solvent accessibility surface area of the HIV-2 gp125 core (PDB accession
number 5CAY) was quantiﬁed using the Web server running DSSP (http://www.cmbi.ru.nl/xssp/) (63). The
relative solvent accessibility (RSA) was calculated as the accessible area divided by the maximum
accessible area of the amino acid in extended tripeptide conﬁrmation (Gly-X-Gly), as previously described
(64). Residues with an RSA value of 5% were considered to be surface exposed (65). The HIV-2 Env
protein (PDB accession number 5CAY) was visualized and surface exposed, and positively selected amino
acids were edited using UCSF Chimera (https://www.cgl.ucsf.edu/chimera/).
Statistical analysis. Statistical analyses were performed in IBM SPSS Statistics 21 using the
two-tailed Mann-Whitney U test (M-W) for continuous variables, the two-tailed Fisher’s exact test
(FET) for categorical variables, Spearman’s rho for correlation analyses, and Friedman’s test for
comparisons of multiple groups. Results from the Friedman’s test showing statistical signiﬁcance
were then analyzed by the Bonferroni-corrected Wilcoxon signed rank test for pairwise comparisons
of groups.
Ethics approval and consent to participate. The study was approved by the ethics committees of
the government of Guinea-Bissau; the University of Lund, Sweden; and the Karolinska Institute, Stock-
holm. Study participants were counselled and provided informed oral consent.
Supplementary information (including supplementary text, ﬁgures, and tables) has been deposited
at https://dochub.com/patrik-medstrand/zqp8z8/supplemntaryinformation_palm_mbio_ver2_180822
?dtNx2HKD__sa_SKWC-XzVE.
Data availability. The data sets generated and analyzed during the current study are available in the
GenBank repository (accession numbers: KM390990 to KM391398).
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